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Abstract.  1 
In the course of our studies on the heterologous expression of giant biosynthetic genes, we discovered 2 
a novel cryptic biosynthetic gene cluster in Streptomyces rochei IFO12908.  During our efforts to 3 
express biosynthetic genes using the host SUKA strain derived from Streptomyces avermitilis, a novel 4 
polyene macrolactam compound designated as JBIR-156 was produced.  We report herein the 5 
cloning and heterologous expression of the JBIR-156 biosynthetic gene cluster, and the isolation, 6 
structure determination, and cytotoxic activity of this novel compound.  7 
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Screening for bioactive microbial secondary metabolites has been performed for more than 70 1 
years.  The search for bioactive natural metabolites has resulted in great benefits to humankind, 2 
although the rate of discovery of skeletally-novel compounds from bacteria has significantly 3 
decreased over time. (ref. 1, 2)  New technologies to discover novel natural compounds are strongly 4 
desired.  To overcome this problem, new techniques to express cryptic biosynthetic gene clusters 5 
for secondary metabolites are needed to access novel compounds.  Furthermore, aside from the 6 
classical techniques including improvement of cultural conditions for wild-type strains, heterologous 7 
expression technology is considered to be one of the most promising strategies since the resultant 8 
production of microbial secondary metabolites can be performed under a common platform.   9 
On the other hand, Streptomyces is known as a representative microorganism to produce potent 10 
natural products. (ref. 3)  Recent advances in genome sequencing projects have revealed that a large 11 
number of biosynthetic gene clusters are encoded in the genome of Streptomyces.  For the expression 12 
of biosynthetic gene clusters, genetically engineered Streptomyces strains such as Streptomyces 13 
coelicolor M1152, M1154, and Streptomyces avermitilis derived SUKA strains, have been developed. 14 
(ref. 4-6)  In these engineered strains, endogenous metabolic pathways were removed to avoid 15 
competition of substrate usages between endogenous and exogenously introduced secondary 16 
metabolites. (ref. 7)  In addition, this engineered host can afford a clean metabolic background, 17 
which makes it easier to isolate relevant compounds.  18 
Despite the many heterologous expression experiments for the production of microbial secondary 19 
metabolites performed over the past two decades, (ref. 8) only a few examples of the heterologous 20 
expression of biosynthetic gene clusters over 100 kb in size have been reported (ref. 9) because it is 21 
extremely difficult to clone and introduce such giant biosynthetic gene clusters into the host strain.  22 
During the course of our focused efforts to establish a technique for the heterologous expression of 23 
large size biosynthetic gene clusters, we developed our technology for cloning larger biosynthetic 24 
gene clusters employing BAC vectors (up to 300 kb genome libraries can be prepared with BAC 25 
vectors).  As a result of our studies, we succeeded in the heterologous production of mediomycin, 26 
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neomediomycin, (ref. 10) and quinolidomicin. (ref. 11)  To express cryptic and/or unreported gene 1 
clusters with our system, we searched biosynthetic gene clusters larger than 100 kb from our in-house 2 
genome sequence data bank consisting of more than 100 actinomycete strains.  Among such large 3 
biosynthetic gene clusters, we selected a gene cluster including type-I PKSs with glutamate mutase 4 
genes, which could produce a macrolactam compound in the genome of Streptomyces rochei 5 
IFO12908.  As well known that macrolactam compounds can exhibit potent cytotoxic activities.  6 
On the other hand, macrolactam compounds are extremely difficult to obtain because of highly 7 
vulnerable character.  It was expected that such unstable compounds showing strong bioactivities 8 
can be obtained by applying our heterologous expression techniques.  Heterologous expression of 9 
the BAC clone containing a whole biosynthetic gene cluster of the type-I PKS resulted in the 10 
production of a novel polyene macrolactam compound designated as JBIR-156 (1).  Here we report 11 
the cloning, heterologous expression of the gene cluster, isolation, structure determination, and brief 12 
biological activities of 1. 13 
We scanned the draft genome sequence of S. rochei IFO12908 strain and found a biosynthetic 14 
gene cluster over 100 kb which encodes 5 polyketide synthases (PKSs).  Among the PKS modules 15 
of JBIR-156 (1), a total of 9 of the 10 modules include the dehydratase (DH) and ketoreductase (KR) 16 
domains, which compose the double bonds at -keto groups of acyl-carrier protein (ACP)-bound 17 
intermediates.  Therefore, this biosynthetic product is expected to consist of highly conjugated 18 
double bonds.  The putative biosynthetic gene cluster including adjacent genes responsible for the 19 
production of the compound was estimated at 140 kb at most.  For cloning of the gene cluster, a 20 
BAC DNA library of the S. rochei IFO12908 strain was prepared as previously described. (ref. 12, 21 
13)  A clone, pKU518F6K295_P1_P9-M23 (insert size: 234 kb), containing the biosynthetic gene 22 
cluster was picked up by PCR screening which amplified the upstream and downstream of the target 23 
gene cluster from the constructed DNA library.  The pKU518F6K295_P1_P9-M23 was introduced 24 
into the SUKA32 strain to obtain a transformant, SUKA32::pKU518F6K295_P1_P9-M23.  The 25 
obtained clone was cultivated in 50-mL test tubes, each containing 15 mL of a seed medium consisting 26 
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of 0.5% glucose, 1.5% Soya Flour and 0.5% yeast extract.  The test tubes were shaken on a 1 
reciprocal shaker (320 r.p.m.) at 27 ˚C for 2 days.  Aliquots (2.5 mL) of the culture were transferred 2 
into 500-mL baffled Erlenmeyer flasks filled with 100 mL of a production medium consisting of 2% 3 
glycerol, 1% molasses, 0.5% casein, 0.1% polypepton and 0.4% CaCO2 (adjusted pH to 7.2 before 4 
sterilization), and cultured on a rotary shaker (180 r.p.m.) at 27 ˚C for 5 days.   5 
We executed comparative analyses of the transformant and null strains of SUKA32.  According 6 
to the structural prediction of the biosynthetic gene cluster of JBIR-156, 1 could show characteristic 7 
polyene UV absorption.  A specific peak showing polyene UV absorption was appeared in the 8 
extract of the mycelial cake of transformant.  The fermentation broth (1 L) was centrifuged to collect 9 
a mycelial cake, which was extracted with 200 mL of acetone three times.  Acetone was evaporated 10 
in vacuo, and the residual aqueous layer was extracted with ethyl acetate twice.  The resultant ethyl 11 
acetate layer was concentrated to dryness (321 mg).  The sample was subjected to ODS RP-MPLC 12 
(Purif-Pack ODS-60 Shoko Scientific Co., Yokohama, Japan) by using a H2O–MeOH stepwise 13 
solvent system (0%, 40%, 60%, 80%, and 100% MeOH).  The 80% MeOH fraction was collected 14 
and lyophilized (30.7 mg).  The fraction was further purified by RP HPLC employing a Develosil 15 
RPAQUEOUS-AR5 C30 column (20 i.d. × 150 mm, Nomura Chemical, Seto, Japan), in isocratic 16 
mode with 55% CH3CN (flow rate 10 ml min–1) to afford a pure sample of 1 (3.6 mg).   17 
Compound 1 was obtained as a brownish powder.  [α]24D −25 (c 0.02, MeOH); UV (MeOH) 18 
λmax (log ε) 264 nm (4.22), 303 nm (4.53), 313 nm (4.54), 348 nm (4.11); IR (ATR) νmax 3400 and 19 
1646 cm−1.  The UV spectrum of 1 suggested that 1 consisted of a polyene structure.  Its molecular 20 
formula was established as C24H29NO2 by HR-ESIMS ([M+H]+, m/z 364.2270, calcd for C24H30NO2, 21 
364.2271).  The structure determination of 1 was performed based on 1H, 13C NMR and a series of 22 
2D NMR analyses, double quantum filtered COSY (DQF-COSY), gradient-enhanced heteronuclear 23 
single quantum coherence with adiabatic pulses (HSQCAD), and gradient-selected heteronuclear 24 
multiple bond correlation using adiabatic pulses (HMBCAD).  The 13C and 1H NMR data for 1 are 25 
listed in Table 1.  The well-resolved DQF-COSY spectrum of 1 indicated two partial structures.  26 
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The sequence from a doublet olefinic methine proton 2-H (δH 5.64) to an olefinic methine proton 18-1 
H (δH 6.15) through olefinic methine protons 3-H (δH 6.33), 4-H (δH 7.35), 5-H (δH 6.87), 6-H (δH 2 
6.33), 7-H (δH 6.55), 8-H (δH 6.62), 9-H (δH 5.69), aliphatic methylene protons 10-H2 (δH 2.27, 2.95), 3 
an oxymethine proton 11-H (δH 4.47, δC 68.7), olefinic methine protons 12-H (δH 5.60), 13-H (δH 4 
5.90), 14-H (δH 6.13), 15-H (δH 6.38), 16-H (δH 5.97), and 17-H (δH 6.36) was observed.  Another 5 
1H sequence was established by the 1H spin system from an olefinic methine proton 19-H (δH 6.17) 6 
to an amide proton NH (δH 7.98) via olefinic methine protons 20-H (δH 6.50), 21-H (δH 5.19), a 7 
methine proton 22-H (δH 3.40) which in turn coupled to methyl protons 24-H3 (δH 0.92) and nitrogen 8 
atom connected methylene protons 23-H2 (δH 2.35, 3.39, δC 45.9).  Although, the 3JH,H value 9 
between 18-H and 19-H (11.3 Hz) was read from a coupled HSQC spectrum, the linkage between C-10 
18 and C-19 was confirmed by the HMBC correlation as described vide infra.  11 
The connectivity between these two moieties was established as follows.  In the HMBC 12 
spectrum, 1H-13C long-range couplings from the olefinic methine proton 17-H (δH 6.36) to an olefinic 13 
methine carbon C-19 (δC 125.9), and from an olefinic proton 20-H (δH 6.50) to an olefinic methine 14 
carbon C-18 (δC 123.3), established the connection between C-18 and C-19.  A macrolactam 15 
structure was established by the 1H-13C long-range couplings from the olefinic protons 2-H, 3-H, 23-16 
H2 and the amide proton 23-NH to an amide carbonyl carbon C-1 (δC 166.9).  Based on the index of 17 
hydrogen deficiency of 1 together with the proton and carbon chemical shifts, it was determined that 18 
a hydroxy group was deduced to be substituted at the position of C-11.  The geometrical 19 
configurations at C-2, C-4, C-6, C-8, C-12, C-14, C-16, C-18 and C-20 were established as Z, E, Z, 20 
Z, E, E, Z, Z and Z, respectively, according to the 3JH,H values, (J2,3 = J6,7 = J8,9 = J16,17 = J18,19 = J20,21 21 
= 10 - 12 Hz and J4,5 = J12,13 = J14,15 = 14 - 16 Hz).  Thus, the gross structure including the geometry 22 
of 1 was established as shown in Figure 1.   23 
We annotated the functions of the genes in the biosynthetic gene cluster as shown in Table S1 24 
and a plausible biosynthetic pathway is illustrated in Figure S2.  The biosynthetic gene cluster for 25 
JBIR-156 resembles those of polyene macrolactams such as vicenistatin, (ref. 14) ML-449 (ref. 15) 26 
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and sceliphrolactam. (ref. 16) The biosynthesis of the starter unit in the PKS of 1 occurs through the 1 
same pathway as that of vicenistatin.  Biosynthesis is initiated from the conversion of L-glutamic 2 
acid to (2S,3S)-3-MeAsp by ORF H and I.  Following this reaction, ORF K, J and E form an 3 
intermediate on a carrier protein ORF L, which is then loaded onto PKS by ORF F (Figure S2). (ref. 4 
17)  Consequently, the absolute configuration at the position of C-22 of 1 is predicted to be S as 5 
shown in Figure S2, because the methyl residue at C-22 is derived from (2S,3S)-3-MeAsp.  The 6 
biosynthetic intermediates on the PKS for the formation of the macrolactam, which is predicted from 7 
the information of its domain organization, are shown in Figure S2.  The intermediates on PKS 8 
deduced from the domain architecture coincide well with the structure of JBIR-156.  The formation 9 
of absolute configurations of chiral carbons substituted by hydroxy residues in type-I PKS can be 10 
regulated by the sequence of KR domains.  The KR domain on Module 6 that introduces the hydroxy 11 
residue at C-11 is of the A-type, forming an L-configuration of the ACP-bound intermediates.  The 12 
other KR domains that reside with DH domains in the other modules are all B-type.  Therefore, the 13 
putative absolute configurations at C-11 and C-22, which are substituted by the hydroxy and the 14 
methyl groups, respectively, are shown in Figure S2.   15 
Since potent cytotoxic activities are often induced by polyene macrolactam compounds, we 16 
examined the cytotoxic activities of 1 against human ovarian adenocarcinoma SKOV-3, malignant 17 
pleural mesothelioma Meso-1 and T lymphoma Jurkat cells.  As the result of cytotoxic test, 1 18 
exhibited cytotoxicities against SKOV-3 and Jurkat cells with the IC50 values of 9.45 and 3.51 M, 19 
respectively.  1 also showed weak cytotoxicity against Meso-1 (IC50 value: > 10 M).  The 20 
cytotoxic activities of 1 were almost the same magnitudes as those of etoposide (IC50 values of 21 
etoposide against SKOV-3, Meso-1 and Jurkat cells were 2.4 M, 39.3 M and 0.5 M, respectively), 22 
while camptothecin showed more potent activities against SKOV-3, Meso-1 and Jurkat cells with 23 
IC50 values of 33 nM, 7,100 nM and 4.3 nM, respectively. 24 
Compound 1 structurally resembles cyclamenol A (ref. 18), vicenistatin and NOVO4 (ref. 19) 25 
aglycons.  Compound 1 was first isolated as the result of heterologous expression of the cryptic 26 
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biosynthetic gene cluster in SUKA host strain, from which endogenous biosynthetic gene clusters 1 
were knocked out.  Since 1 consists of polyene moieties well known to be vulnerable to oxygen, 1 2 
is degraded through the isolation process in which compounds are exposed to oxygen.  The cultural 3 
metabolite of wild-type producing strain S. rochei IFO12908 contains many impurities, therefore it 4 
requires more isolation steps to obtain pure sample of 1.  Moreover, the production yield of 1 by 5 
wild type strain is about 4-fold less than that of the SUKA22 transformant.  Comparatively the clean 6 
metabolic background and the higher production yield of heterologous expression in SUKA32 strain 7 
make it easier the isolation process.  Thus, our heterologous expression system could be a promising 8 
technology for the production of even unstable compounds.  Further studies on the heterologous 9 
expression of various cryptic biosynthetic genes are now underway. 10 
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